Swiss firm Lonza said Wednesday it will open a new production line for the drug substance in Moderna’s COVID-19 vaccine, making it possible to churn out hundreds of millions more jabs per year.
Swiss firm Lonza said Wednesday it will open a new production line for the drug substance in Moderna’s COVID-19 vaccine, making it possible to churn out hundreds of millions more jabs per year.
